June 29, 2018 / 8:45 AM / 19 days ago

BRIEF-Novartis CEO Says Main Listing Of Alcon Will Be In Switzerland

June 29 (Reuters) - Novartis AG:

* CEO SEES NO IMPACT ON NOVARTIS’S BOLT-ON M&A STRATEGY FOLLOWING ALCON SPINOFF

* CEO SAYS GOODWILL FROM ALCON WILL BE SPLIT EVENLY BETWEEN RETAINED PRESCRIPTION EYE DRUGS THAT NOVARTIS IS KEEPING, ALCON COMPANY BEING SPUN OFF TO SHAREHOLDERS

* CEO SAYS MAIN LISTING OF NEW ALCON COMPANY WILL BE IN SWITZERLAND FOLLOWING SPINOFF, WITH SHARES ALSO TRADING IN NEW YORK Source text for Eikon: Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below